# Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

> **NCT04922047** · PHASE1,PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Antineoplastic Agents
- Urinary Bladder Diseases
- Tislelizumab Antineoplastic Agents, Immunological

## Interventions

- **DRUG:** tislelizumab and BCG

## Key facts

- **NCT ID:** NCT04922047
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06
- **Primary completion:** 2021-12
- **Final completion:** 2023-08
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922047, "Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04922047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*